Welcome to the TLMdX Media page. Here you’ll find information about AASLD press releases, media registration and AASLD's media policies and guidelines.
AASLD extends complimentary registration to The Liver Meeting Digital Experience ™ to credentialed, eligible media. Registered media will have access to all general sessions, the exhibit hall, poster area, the Postgraduate Course, and the Basic Science Symposium.
Please review our media policies and guidelines for eligibility requirements.
AASLD will provide registered media with an on-demand alternative to a press conferences during The Liver Meeting Digital Experience ™. The press conference is an opportunity for invited investigators to share their findings with members of the media. Media will have access to a private, pre-recorded video, featuring the authors of the abstracts highlighted in the press releases (to be released under embargo prior to the start of the meeting). Media will have the option to connect directly with authors through the networking modules available on the platform, or the AASLD media team can facilitate the scheduling of interviews.
NOTE: The on-demand press conference will not be made available to the public
Press Conference Slate
Media kits, with press releases will be emailed to registered media in advance of the meeting. All press releases will be posted online after the embargo lifts at 8 AM ET on Friday, November 13.
The American Association for the Study of Liver Diseases appreciates your interest in covering The Liver Meeting Digital Experience™. Below you will find a complete listing of the eligibility requirements, guidelines, and policies for members of the press who wish to attend The Liver Meeting Digital Experience ™.
Read all of the sections below carefully, as there have been updates to our policies.
Accepted abstracts are made available to the public on the AASLD website in early October and are published in the December supplement of HEPATOLOGY. Late-breaking abstracts will be available in early November (more information to come), and are published in the December issue of HEPATOLOGY. Information contained in those abstracts may not be released until the abstracts appear on the AASLD website. Academic institutions, private organizations, and companies with products whose values may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract on the AASLD website. However, information beyond that contained in the abstract, e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional or new information that will be available at the time of the meeting is embargoed from release to the general public until 8:00 am ET Friday, November 13.
Information released prior to this day is a violation of the AASLD Abstract Embargo Policy and the abstract is subject to withdrawal from The Liver Meeting Digital Experience™ program. Authors are responsible for notifying financial and other sponsors about this policy.
AASLD may allow for exceptions, on a case-by-case basis, to the Abstract Embargo Policy for compelled disclosures mandated by federal securities laws. However, AASLD requires the company President, General Counsel, or other appropriate official of a company seeking such an exception to attest in writing to the specific facts in support of the request, including exactly how the securities laws are implicated, with statutory citation(s). General statements of the need to comply with the law will not be considered sufficient. Requests for an exception must be sent to AASLD. AASLD requires a minimum of five (5) days from receipt of the request to evaluate the request. In granting an exception, AASLD requires the company to state in their public disclosure that the complete and final results will be presented at The Liver Meeting®. AASLD will also require the inclusion of unreleased and unique data in such a presentation at The Liver Meeting Digital Experience ™.
Public release of a journal article relevant to the abstract will be considered an exception to the Embargo Policy if at the time of the abstract submission deadline, the decision concerning the manuscript had not been revealed to the authors.
Journalists and contributing freelancers, employed by a recognized news organization, are eligible to apply for press registration. To be eligible for press registration, media in all categories must be directly involved in the creation of news content for organizations that meet these criteria:
Bloggers will receive press credentials on a case-by-case basis. Please include a link to recent liver disease, hepatology, or health care science coverage with your registration for credentials. Finally, all blogs must demonstrate the dissemination of original, editorial news coverage and editorial freedom from advertisers and/or sponsors (single-sponsored blogs will not receive credentials; blogs with advertising must have multiple advertisers clearly identified).
NOTE: AASLD has the right to inspect the credentials of anyone registering as media and reserves the right to refuse to register any individual as press.
The following individuals are not eligible for media registration:
NOTE: AASLD prohibits the development of CME content based on information presented at its meetings. CME writers and editors, and those writers and editors working on behalf of organizations that have written CME based on AASLD meetings, are not eligible for press passes.
Insignias and logos of the AASLD, The Liver Meeting®, The Liver Meeting Digital Experience ™ or AASLD Foundation are proprietary marks. Use of these in any fashion, by any entity, for any purpose, is prohibited without the written permission of AASLD. The use of insignias, logos and images that mislead the intended audience to believe that a piece or production is coming from the AASLD is strictly prohibited and will result in the denial of press credentials for future meetings.
If you intend to present coverage of The Liver Meeting Digital Experience ™ in a dedicated website or newsletter, please include the following disclaimer at the top of your piece: This information is brought to you by [insert organization name] and is not sponsored by, nor a part of, the American Association for the Study of Liver Diseases or The Liver Meeting®or The Liver Meeting Digital Experience ™. Additionally, you may not use the AASLD or The Liver Meeting® or The Liver Meeting Digital Experiences ™ logos or names to imply affiliation.
AASLD reserves the right to request promotional activities violating this policy be edited or removed. Failure to comply with these guidelines may result in loss of press credentials for future meetings.
AASLD will not display exhibitor press materials in the digital Newsroom. Press materials on research presented during the meeting must be given attribution to The Liver Meeting Digital Experience ™ 2020. NOTE: AASLD does not review/approve press materials. Exhibitors are responsible for reviewing and adhering to the Embargo Policy (found in the tab above) and should refrain from using the AASLD logo, The Liver Meeting® logo, The Liver Meeting Digital Experience ™ and should not imply an endorsement from AASLD.